Results 81 to 90 of about 51,276 (310)

Rivaroxaban in Patients with Heart Failure

New England Journal of Medicine, 2019
restriction
Jaewon Oh, Seok Min Kang
openaire   +4 more sources

Deep Vein Thrombosis Caused by Drug‐Induced Giant Bladder Diverticulum in Long‐Term Use of Antipsychotic Drugs: Case Report and Literature Review

IJU Case Reports, EarlyView.
ABSTRACT Introduction Bladder diverticulum rarely causes deep vein thrombosis (DVT) due to compression of leg veins. However, only a few cases have been reported to date. In this article, we report the first known case of DVT caused by a giant bladder diverticulum associated with long‐term use of antipsychotic medication.
Kazuki Sato, Kotaro Hirai, Yumiko Yokomizo, Azumi Fujioka, Yuki Ito, Yuichi Sugiyama, Yuko Hishiki   +6 more
wiley   +1 more source

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundVenous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for ...
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Brahim Bookhart, Concetta Crivera, Jeff Schein   +7 more
doaj   +1 more source

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits

Open Life Sciences, 2022
The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or ...
Yin Lu, Qi Yuan, Ge Zhiru, Li Jiajin
doaj   +1 more source

New oral anticoagulants and their reversal agents [PDF]

, 2018
Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana, Diaconu, Camelia C, Laslo, Crista L, Marcu, Dragos, Neagu, Tiberiu P, Paduraru, Dan N, Pantea Stoian, Anca, Socea, Bogdan, Socea, Laura I, Stanescu, Ana Maria Alexandra   +9 more
core   +1 more source

Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial [PDF]

, 2012
Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and requires careful safety management. The aim of this study is to investigate whether a best practice model that applies major elements of case ...
A Siebenhofer, A Siebenhofer, A Siebenhofer, Andrea Berghold, Andrea Siebenhofer, AS Go, C Guethlin, C Heneghan, C Heneghan, CD Furberg, DE Morisky, EH Wagner, Ferdinand M Gerlach, FR Rosendaal, I Schafer, Ina Roehl, J Ansell, J Gensichen, J Gensichen, J Hirsh, Juliana J Petersen, K Goetz, K Saal, Karola Mergenthal, Lisa R Ulrich, M Connock, M Man-Son-Hing, M Nabauer, M Ufer, M von Korff, MJ Campbell, MJ Campbell, MR Patel, N Dagres, N Oake, PT Sawicki, R Bucheler, S Schulman, Sandra Rauck, Sebastian Harder, SJ Connolly, SL Norris, T Rosemann, TD Christensen, TD Hua, The EuroQol Group   +45 more
core   +2 more sources

Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan

The Journal of Clinical Pharmacology, EarlyView.
Abstract In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a
Akinori Nakashima, Akihide Tsujimoto, Masako Saito, Jun Takeda, Makiko Natori, Satoshi Shoji   +5 more
wiley   +1 more source

The discovery of rivaroxaban: translating preclinical assessments into clinical practice

Frontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza, Elisabeth ePerzborn, Scott D Berkowitz   +2 more
doaj   +1 more source

Vascularized Tumor‐on‐a‐Chip Model as a Platform for Studying Tumor‐Microenvironment‐Drug Interaction

Macromolecular Bioscience, EarlyView.
Vascularized tumor‐on‐a‐chip platforms replicate human tumor microenvironments by integrating perfusable vessels and stromal elements in microfluidic systems. These models enable dynamic assessment of drug delivery and therapeutic response under physiologically relevant flow, offering enhanced predictive value for cancer treatment.
Hyelim Kim, Seung‐Woo Cho, Hong Nam Kim   +2 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source